ModraPac005, a tablet formulation of paclitaxel developed by Modra, is currently undergoing Phase I studies. Paclitaxel, a member of the taxane class of chemotherapeutics, is also one of the most frequently applied anti-cancer drugs globally and shares a similar efficacy and toxicity profile with docetaxel. Paclitaxel is generally considered slightly less toxic and also requires IV- administration that is formulated with the toxic excipients chremophor EL and ethanol.
With initial focus on taxane-based chemotherapeutics, we will bring our oral formulation technology to other areas of oncology and work together with cancer leaders and innovators to expedite the development of next-generation cancer regimens.



Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


Meet us at one of the following events:      
Read more